We had the great pleasure of meeting with Prof. Kevin Garey (University of Houston College of Pharmacy, Houston, TX, USA) to discuss the health burden of C difficile infections, and the limitations of current treatment approaches. Watch Part 2 of the interview here.
The abstract entitled: ‘The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial’ was presented at IDWeek 2021 (Virtual), 28 September – 3 October 2021.
Questions:
- Could you give us an overview of the health burden of C difficile infections? (0:12)
- What are the limitations of current approaches to treating recurrent C difficile infections? (0:39)
Disclosures: Kevin Garey has research grants paid to his university from Seres Therapeutics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of IDWeek, Virtual 2021
